Applying Next-Generation In Vitro Antibody Libraries to Drug Discovery
Andrew Bradbury, PhD
In vitro libraries have recently demonstrated the ability to deliver antibodies with affinities comparable to those obtained by immunization
Andrew Bradbury, PhD
Andrew Bradbury is a cofounder and chief scientific officer of Specifica, a Q2 Solutions company. With more than 40 years of experience in the field of recombinant antibodies and display technologies, he has developed and employed novel technologies in antibody discovery. Bradbury has frequently served as an expert witness in antibody patent cases involving some of the world’s best-selling antibody drugs.
Bradbury has published more than 170 peer-reviewed papers and is the inventor on numerous patents and patent applications. He holds a PhD from Cambridge University, where he studied under Nobel Laureate Cesar Milstein, the inventor of monoclonal antibodies.